Last reviewed · How we verify
Vonoprazan, Amoxicillin, Levofloxacin
Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by blocking the H+/K+ ATPase enzyme.
Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by blocking the H+/K+ ATPase enzyme. Used for Treatment of gastroesophageal reflux disease (GERD), Eradication of Helicobacter pylori.
At a glance
| Generic name | Vonoprazan, Amoxicillin, Levofloxacin |
|---|---|
| Sponsor | Aga Khan University |
| Drug class | Potassium-competitive acid blocker (P-CAB) |
| Target | H+/K+ ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
By blocking the H+/K+ ATPase enzyme, vonoprazan reduces gastric acid secretion, which can help alleviate symptoms of gastroesophageal reflux disease (GERD). This mechanism is distinct from traditional proton pump inhibitors (PPIs), which also inhibit gastric acid secretion but through a different mechanism. Vonoprazan's P-CAB mechanism may offer improved efficacy and reduced side effects compared to PPIs.
Approved indications
- Treatment of gastroesophageal reflux disease (GERD)
- Eradication of Helicobacter pylori
Common side effects
- Headache
- Diarrhea
- Nausea
Key clinical trials
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication (PHASE4)
- Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection (PHASE4)
- Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori (PHASE3)
- Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication (PHASE3)
- The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
- One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL (PHASE3)
- The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |